Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration

Dec 13 2017

• By Joseph Haas and Ying Huang

DealWatch_1200x675

Related Content

Cannabis Derivative Sativex 'Shows Promise In US Patients' Despite Further Phase III Failure

Oct 29 2015

Gilead Acquisition Of Cell Design: The Next Logical Step

Dec 08 2017

Hisun-Pfizer Split: What Went Wrong And What Next?

Dec 08 2017

Deal Watch: Taking Care Of Business Before J.P. Morgan

Jan 06 2017

Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH

Jul 11 2017

Synlogic Moves Synthetic Biotics To The Clinic For Rare Metabolic Disease

Oct 30 2017

Takeda Paves The Way For Myovant With Phase III Fibroid Success

Oct 03 2017

Related Companies

Vertex Pharmaceuticals Incorporated

GW Pharmaceuticals plc

Otsuka Holdings Co., Ltd.

Allergan plc

Repros Therapeutics, Inc.

Bayer AG

Takeda Pharmaceutical Co. Ltd.

Myovant Sciences Ltd.

AbbVie Inc.

Neurocrine Biosciences, Inc.

Eli Lilly and Company

Bristol Myers Squibb Company

OncoTracker Inc.

Fred Hutchinson Cancer Research Center

Ono Pharmaceutical Company, Ltd.

Cyclenium Pharma Inc.

Arena Pharmaceuticals, Inc.

Ascletis Pharma, Inc.

I-Mab

Almirall SA

Athenex, Inc.

Synlogic, Inc.

Xynomic Pharmaceuticals Holdings, Inc.

Johnson & Johnson

Memorial Sloan Kettering Cancer Center

Johnson & Johnson

Pharmacyclics, Inc.

HitGen Inc.

Boehringer Ingelheim GmbH

Kite Pharma, Inc.

Gilead Sciences, Inc.

Zhejiang Hisun Pharmaceutical Co. Ltd.

Additional Topics

Deals M & A Business Strategies Commercial Companies BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window